Navigation Links
Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
Date:5/24/2010

oing trials of our ZFN-based technology.  At the same time, with our collaborators, we continue to define and develop new therapeutic opportunities."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
3. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
4. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
5. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
6. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
7. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
8. Sangamo Announces Pricing of Public Offering of Common Stock
9. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
10. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
11. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Partnership to Focus on Materials for Food and ... Del., Sept. 26 ,DuPont (NYSE: DD ) ... starch-based biopolymers, today announced plans to,collaborate in the ... Plantic(R) technology. Plans include the collaborative development ...
... Mylan Laboratories Inc.,(NYSE: MYL ) will host ... acquisition. Pending the closing, the investor day will take ... Robert J. Coury, Mylan,s,Vice Chairman and Chief Executive Officer, ... Generics and Matrix Laboratories will,provide a detailed financial and ...
... TUCSON, Ariz., Sept. 26 Clinically ... patients in,hospitals and health care facilities, is ... industry,s first dual-handset cordless phone,ClearLink(TM) Cordless. ... patented,dual-handset phone now known as ClearLink(TM), this ...
Cached Biology Technology:DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 2DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 3Industry-First Telephone for Health Care Developed by CyraCom 2
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/12/2014)... BEACH GARDENS, Fla. , Nov. 12, 2014 /PRNewswire/ ... solutions, announced today that its U.are.U ® fingerprint ... retail bakery chain in Central Mexico ... in June 2014 to eliminate payroll issues caused by ... Prior to installing the U.are.U fingerprint readers, Montparnasse relied ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... Two renowned universities, the Nanyang Technological University ... United Kingdom (UK), this morning signed an agreement ... research. The aim of the programme ... at both universities, promote joint ventures and access ...
... of the Max Delbrck Center for Molecular Medicine (MDC) ... Weizscker Award of the National Academy of Sciences Leopoldina ... bioinformatician, molecular biologist and GDR civil rights activist received ... personal and political courage. The award was presented to ...
... at the University of California, Riverside have won awards ... Timothy Paine , a professor of entomology, won ... an entomologist who has contributed to the American horticulture ... of entomology, won the Recognition Award in Entomology, which ...
Cached Biology News:Professor Jens Reich first recipient of the Carl Friedrich von Weizsacker award 2Professor Jens Reich first recipient of the Carl Friedrich von Weizsacker award 33 UC Riverside entomologists honored by Entomological Society of America 2
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... l-[35S]in vitro cell labeling mix, ... *Aqueous solution stabilized with 0.1% ... pyridine 3,4-dicarboxylic acid. *Amino acid ... labeling containing l-[35S]Methionine and l-[35S]Cysteine. ...
...
Biology Products: